|
|
C5a |
|
Vaxjo ID |
495 |
|
Vaccine Adjuvant Name |
C5a |
|
Adjuvant VO ID |
VO_0005772
|
|
Description |
dipeptide vaccine adjuvant that is agonist of human C5a and induces Th1-biased reponse |
|
Stage of Development |
Research |
|
Location Licensed |
USA |
|
Host Species for Testing |
Mouse |
|
Second Host Species for Testing |
Rabbit |
|
Components |
YSFKPMPLaR (uppercase letters designate the l stereoisomeric form of the amino acids and lowercase letters designate the d stereoisomeric form) |
|
Structure |
dipeptide |
|
Preparation |
c5a-active constructs were generated by the covalent attachment of the HBsAg CTL epitope to the N terminus of the C5a agonist (IPQSLDSWWTSLYSFKPMPLaR, IPQSLDSWWTSLRRYSFKPMPLaR, and IPQSLDSWWTSLRVRRYSFKPMPLaR). This positioning of the CTL epitope relative to the C5a agonist leaves the biologically important conformational features expressed in the C-terminal region of YSFKPMPLaR free to interact with C5aRs expressed on the cells involved in Ag uptake and processing |
|
Function |
Type: peptide vaccine adjuvant. Induces Th1-biased immune profile. interacts with C5aRs expressed on the surface of APCs to induce the synthesis and release of cytokines that activate T cells |
| References |
Ulrich et al., 2000: Ulrich JT, Cieplak W, Paczkowski NJ, Taylor SM, Sanderson SD. Induction of an antigen-specific CTL response by a conformationally biased agonist of human C5a anaphylatoxin as a molecular adjuvant. Journal of immunology (Baltimore, Md. : 1950). 2000; 164(10); 5492-5498. [PubMed: 10799917].
|
|
